Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Many leading stocks flashed buy signals Friday as the market rebounded, including Nvidia. CEO Jensen Huang gives a key speech ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

Storm Chaser Aaron Jayjack is in Kansas City, Missouri, where multiple trucks and other vehicles were seen sliding off ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...